Sat, Jan 31, 2015, 3:07 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

  • mikeadd@bellsouth.net mikeadd Nov 3, 2011 4:17 PM Flag

    3Q results/ some anyway

    Optimer reported total revenues for the third quarter of 2011 of $11.1 million, compared $669,000 for the third quarter in 2010. This includes net product sales of $10.6 million recognized from the sale of DIFICID™. Optimer recognizes product sales of DIFICID upon delivery of product to its wholesalers.
    • For the quarter ended September 30, 2011, the $10.6 million in net sales to wholesalers reflected a total of 4,335 DIFICID treatments
    o 2,505 DIFICID treatments were shipped from wholesalers to hospitals, retail pharmacies and long-term care facilities in the quarter ended September 30, 2011
    • 535 hospitals had ordered DIFICID as of September 30, 2011
    • 304 hospitals had placed DIFICID on formulary, and 346 hospital formulary reviews were pending as of October 21, 2011.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Sales for Q3 only make up 45 DAYS in the 3rd qtr. - Product was not available until mid - August - if you pro-rata the sales run for the qtr - it's more $22 Million . . . just my opinion.

    • People need to understand that this drug is brand new, and there is an adoption rate that must be factored in. As long as scripts pick up each qtr, which I believe they will, this company has a very bright future. Let the bashers bash ....

    • Looks good to me, but tomorrows action will be the telltale ...

    • mikeadd@bellsouth.net mikeadd Nov 3, 2011 4:23 PM Flag

      Additional Business Updates
      • In September 2011, Optimer and its collaboration partner, Astellas Pharma Europe Ltd., received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for DIFICLIR™ (fidaxomicin) tablets for the treatment of adults suffering from a Clostridium difficile infection
      • In October 2011, Optimer established a Canadian subsidiary and appointed a country manager to support efforts to sell DIFICID directly into Canadian markets, if approved. In addition, the company filed a New Drug Submission to Health Canada for DIFICID in the treatment of CDAD and was granted a priority review from the Canadian authorities
      • In November 2011, the Company made a strategic decision to discontinue the development of Pruvel (prulifloxacin) as a treatment for traveler's diarrhea. The Company notified Nippon Shinyaku, Co. Ltd. of its decision to terminate the license agreement for Pruvel and will return all rights to the compound to Nippon Shinyaku

    • mikeadd@bellsouth.net mikeadd Nov 3, 2011 4:22 PM Flag

      3. Patient Access
      Optimer estimates 84% of targeted health plan lives currently have access to DIFICID. As of October 21, 2011, 324 patients have been provided access to DIFICID via the company's Patient Assistance Program.
      4. Medical Affairs/Education
      Optimer's medical affairs team has been communicating with the medical community to help educate physicians about Clostridium difficile-associated diarrhea (CDAD) and the clinical benefits DIFICID can potentially have in treating CDAD patients. In addition to active participation at medical conferences such as the ICAAC and IDSA annual meetings, since launch Optimer has completed or sponsored more than 200 programs, symposia and other events attracting more than 10,000 attendees or participants.

    • mikeadd@bellsouth.net mikeadd Nov 3, 2011 4:21 PM Flag

      Selling, general and administrative expense for the third quarter of 2011 was $26.9 million, compared to $4.8 million for the third quarter of 2010, an increase of $22.1 million. The increase was related to the build-up of Optimer's commercial infrastructure for the launch of DIFICID as well as a significant increase in related marketing expenses. In addition, Optimer expensed $2.9 million of service fees in the third quarter of 2011 under its co-promotion agreement with Cubist Pharmaceuticals, Inc.
      Research and development expense for the third quarter of 2011 was $10.4 million, compared to $8.1 million for the third quarter of 2010, an increase of $2.3 million. The increase was primarily due to higher health economics research, pharmacovigilance, medical affairs and publication expenses. The increase was offset by a decrease in DIFICID and Pruvel development expenses.
      As of September 30, 2011, Optimer held cash, cash equivalents and short-term investments of $129.4 million and had 46,645,252 shares outstanding.
      DIFICID Launch Update
      1. DIFICID Sales
      For the period of July 19, 2011, the date of DIFICID's first sales, through September 30, 2011, DIFICID's net sales of $10.6 million represent 4,335 treatments shipped from Optimer's distribution facility to its wholesalers, of which 2,505 treatments were shipped from the wholesalers to hospital pharmacies, retail pharmacies and long-term care facilities.
      Of the 2,505 treatments shipped from wholesalers to hospital pharmacies, retail pharmacies and long-term care facilities during the third quarter of 2011, 884 treatments were shipped in August, the first full month of DIFICID sales. In September, which includes sales for a five week period, Optimer's wholesalers shipped 1,400 treatments.
      2. Hospital Formularies
      As of October 21, 2011, DIFICID was on formulary at 304 hospitals. As of September 30, 2011, approximately 535 hospitals had ordered and dispensed DIFICID in their facilities, and 41% of hospital orders were repeat orders.

    • mikeadd@bellsouth.net mikeadd Nov 3, 2011 4:20 PM Flag

      more:
      Selling, general and administrative expense for the third quarter of 2011 was $26.9 million, compared to $4.8 million for the third quarter of 2010, an increase of $22.1 million. The increase was related to the build-up of Optimer's commercial infrastructure for the launch of DIFICID as well as a significant increase in related marketing expenses. In addition, Optimer expensed $2.9 million of service fees in the third quarter of 2011 under its co-promotion agreement with Cubist Pharmaceuticals, Inc.
      Research and development expense for the third quarter of 2011 was $10.4 million, compared to $8.1 million for the third quarter of 2010, an increase of $2.3 million. The increase was primarily due to higher health economics research, pharmacovigilance, medical affairs and publication expenses. The increase was offset by a decrease in DIFICID and Pruvel development expenses.
      As of September 30, 2011, Optimer held cash, cash equivalents and short-term investments of $129.4 million and had 46,645,252 shares outstanding

    • mikeadd@bellsouth.net mikeadd Nov 3, 2011 4:19 PM Flag

      more:
      only a few months since our first DIFICID sale on July 19th we've seen significant interest in DIFICID converting into uptake and adoption. We reported $10.6 million in sales to our wholesalers in the third quarter, and we expect continued strong uptake as the launch progresses," said Pedro Lichtinger, President and CEO of Optimer. "This confirms our belief that DIFICID meets the need for a Clostridium difficile-associated diarrhea treatment addressing the problem of recurrence by providing a sustained clinical response. As the medical community becomes more familiar with and recognizes the value of DIFICID, we anticipate that adoption will continue."
      Optimer reported a net loss for the third quarter of 2011 of $26.4 million, or ($0.57) per share, on both a basic and diluted basis, as compared to a net loss for the third quarter of 2010 of $11.8 million, or ($0.30) per share, on both a basic and diluted basis.

 
OPTR
12.780.0000(0.00%)Oct 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.